Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vanda Pharmaceuticals (VNDA) Shares Outstanding (Diluted Average) (2016 - 2025)

Vanda Pharmaceuticals (VNDA) has disclosed Shares Outstanding (Diluted Average) for 17 consecutive years, with $58.9 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Diluted Average) rose 1.34% to $58.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $58.9 million through Dec 2025, up 1.34% year-over-year, with the annual reading at $58.9 million for FY2025, 1.34% up from the prior year.
  • Shares Outstanding (Diluted Average) hit $58.9 million in Q4 2025 for Vanda Pharmaceuticals, roughly flat from $58.9 million in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $59.0 million in Q2 2025 to a low of $56.1 million in Q1 2022.
  • Historically, Shares Outstanding (Diluted Average) has averaged $57.5 million across 5 years, with a median of $57.5 million in 2023.
  • Biggest five-year swings in Shares Outstanding (Diluted Average): increased 3.32% in 2021 and later decreased 1.13% in 2022.
  • Year by year, Shares Outstanding (Diluted Average) stood at $56.9 million in 2021, then increased by 0.11% to $57.0 million in 2022, then increased by 1.01% to $57.6 million in 2023, then rose by 1.03% to $58.1 million in 2024, then increased by 1.34% to $58.9 million in 2025.
  • Business Quant data shows Shares Outstanding (Diluted Average) for VNDA at $58.9 million in Q4 2025, $58.9 million in Q3 2025, and $59.0 million in Q2 2025.